Our findings also showed that breast cancer patients with TOP2A, ERBB2, and MYC amplification (amp) achieved higher pCR rates than wtTOP2A, ERBB2, and MYC (56.3% (n=1) vs 13.8% (n=1), 28.4% (n=1) vs 6.1% (n=1), and 13.7% (n=1) vs 11.2% (n=1), respectively) when treated with TA regimens. Here, ERBB2 is linked to breast carcinoma.